12 Health Care Stocks Moving In Friday's Intraday Session
GainersNovo Integrated Sciences (NASDAQ:NVOS) shares rose 120.0% to $0.99 during Friday's regular session. The company's market cap stands at $18.9 million. Anebulo Pharmaceuticals (NASDAQ:ANEB) share
Genprex to Present at the 2024 BIO International Convention
Presentation to Highlight the Company's Gene Therapies for Cancer and Diabetes AUSTIN, Texas — (May 30, 2024) — Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical
Genprex | 10-Q: Quarterly report
HC Wainwright & Co. : Genprex (GNPX.US) rating was reaffirmed and adjusted from buy to buy, with a target price of $10.00.
HC Wainwright & Co. : Genprex (GNPX.US) rating was reaffirmed and adjusted from buy to buy, with a target price of $10.00.
HC Wainwright & Co. Reiterates Buy on Genprex, Maintains $10 Price Target
HC Wainwright & Co. analyst Yi Chen reiterates Genprex (NASDAQ:GNPX) with a Buy and maintains $10 price target.
Genprex Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/15/2024 306.5% HC Wainwright & Co. → $10 Reiterates Buy → Buy 04/04/2024 306.5% HC Wainwright & Co. → $
Genprex's Promising Clinical Trials and Leadership Drive Buy Rating
Genprex Dosing Subjects in Trial of Combination Therapy for Small-cell Lung Cancer
Genprex Doses First Patient in Acclaim-3 Clinical Study of Reqorsa® Immunogene Therapy in Combination With Tecentriq® to Treat Small Cell Lung Cancer
Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for...
Genprex Doses First Patient in Acclaim-3 Clinical Study of Reqorsa Immunogene Therapy in Combination With Tecentriq to Treat Small Cell Lung Cancer
Expects to Initiate the Phase 2 Expansion Study in the Second Half of 2024 Acclaim-3 Study Supported by FDA Orphan Drug and Fast Track Designations AUSTIN, Texas — (May
Genprex Appoints Toscano As Chairman
Press Release: Genprex Announces the Appointment of Jose A. Moreno Toscano as Chairman of the Board of Directors
Genprex Announces the Appointment of Jose A. Moreno Toscano as Chairman of the Board of Directors PR Newswire AUSTIN, Texas, May 13, 2024 Follows the Recent Appointment of Ryan Confer as Genprex Pr
Genprex Announces the Appointment of Jose A. Moreno Toscano As Chairman of the Board of Directors
Follows the Recent Appointment of Ryan Confer as Genprex President and CEO and to its Board of Directors AUSTIN, Texas — (May 13, 2024) — Genprex, Inc. ("Genprex" or the "Company")
Genprex Co-founder, CEO Passes Away
Genprex Co-Founder, CEO Rodney Varner Dies of Cancer
By Sabela Ojea Genprex said co-founder, chief executive and chairman of the board Rodney Varner has died of sudden cancer complications. The clinical-stage therapy company developing therapies for p
Genprex Names Ryan Confer as CEO, President >GNPX
Genprex Names Ryan Confer as CEO, President >GNPX
Genprex: Chairman, CEO Rodney Varner Dies
Genprex: Chairman, CEO Rodney Varner Dies
Press Release: Genprex Announces the Passing of Its Co-Founder and Chief Executive Officer, Rodney Varner
Genprex Announces the Passing of its Co-Founder and Chief Executive Officer, Rodney Varner PR Newswire AUSTIN, Texas, May 8, 2024 Ryan Confer Appointed Genprex President and CEO and to its Board of
Genprex Announces the Passing of Its Co-Founder and Chief Executive Officer, Rodney Varner
Ryan Confer Appointed Genprex President and CEO and to its Board of Directors AUSTIN, Texas — (May 8, 2024) — Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-s
Genprex to Present and Participate at Upcoming May Investor and Industry Conferences
AUSTIN, Texas — (May. 1, 2024) — Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with